[ TRANSACTION RECORD ]
Bristol Myers Squibb Investment in BMS Karuna Platform — 2023
VERIFIED VECTOR
ID: 002216 · tx-312
M SOURCE NODE — FUNDER
$14,000,000,000
EQUITY
22/12/2023
Q DESTINATION NODE — RECIPIENT
Funder Profile
[ M ]
Recipient Profile
[ Q ]
Intelligence Note
Bristol Myers Squibb entered into an agreement to acquire Karuna Therapeutics for 14 billion dollars to expand its presence in neuroscience and psychiatric drug development. This transaction centers on novel treatments for schizophrenia and other complex brain disorders. This deal highlights the high institutional value of transformative neurological therapies in the global healthcare and biotech market.